You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes
SBC: REMD BIOTHERAPEUTICS INC. Topic: NIDDKDESCRIPTION provided by applicant Fast Track Insulin remains the primary and often the only treatment for type diabetes mellitus T D However it is associated with chronic iatrogenic hyperinsulinemia secondary hyperlipidemia higher incidence and severity of cardiovascular complications and life threatening hypoglycemia events A higher mortality vs due to cardiovascular ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Protection and Treatment of the Ocular Surface Barrier
SBC: PROTERIS BIOTECH, INC. Topic: NDESCRIPTION provided by applicant Dry eye a group of disorders that affects million people over the age of in the USA today is characterized by inadequate hydration and lubrication of the ocular surface The final common pathway for all types of dry eye is disruption of the ocular surface barrier which can be assessed by quantifying uptake of water soluble dyes applied topically to the ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Ultrasensitive Point-of-Care Diagnostics of Viral Biomarkers and Infectious Diseases
SBC: ARISAN THERAPEUTICS INC Topic: NIAIDProject Summary Linking infectious agent diagnostics to clinical decision making at the point of care requires a fast highly sensitive and simple to use method that takes into account the infrastructure and workflow in clinical settings of both developing and developed regions In addition being able to distinguish among multiple potential infectious pathogens in a single test is of great impor ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
improving Cas9 mediated homologous recombination in pluripotent stem cells
SBC: APPLIED STEMCELL, INC. Topic: 200DESCRIPTION provided by applicant Gene correction therapy is one of the most important application directions in regenerative medicine Scientists are exploring various approaches to introduce targeted mutations corrections to pluripotent stem cells PSCs to establish disease models and or to develop therapeutic agents Emerging technologies such as Zinc Finger Nucleases ZFNs Transcription ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing novel RPPA for the detection of metastatic prostate cancer
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: 102PROJECT SUMMARY Reverse phase protein arrayRPPAhas emerged as a promising antibody based highly quantitative proteomic technology suitable for profiling proteins in hundreds to thousands of patient samplesThe throughputsensitivityand cost effectiveness of RPPAtogether with its ability to deal with minuscule sample amountshave propelled applications of the technology in basicpreclinical and clinica ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Novel QcrB Inhibitors for the Treatment of Tuberculosis
SBC: LGENIA INC. Topic: NIAIDAbstract Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the biggest killer among infectious diseases. TB is also responsible for a quarter of all deaths associated with Antimicrobial Resistance (AMR). It is projected that by 2050, 75 million people, or one person every 12 seconds, will die due to AMR associated with TB. Long treatment times and increasing resistance to TB drugs ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
High Density Cell Respirator (HDCR) for the production of vectors, viruses and vaccines
SBC: XDemics Corporation Topic: NCATSPROJECT SUMMARY/ABSTRACT This Phase I/II STTR Fast Track proposal responds to the call from the 2018/2019 NCATS SBIR/STTR Research Priorities to develop technologies so that “new treatments and cures for disease can be delivered to patients more quickly”. The production of life-altering gene editing vectors, cancer killing viruses, and life- saving vaccines currently depends on traditional cel ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Clinical feasibility of a non-invasive, low-cost wearable for measuring air trapping in COPD
SBC: Respira Labs, Inc. Topic: NHLBIABSTRACTChronic Obstructive Pulmonary Disease (COPD) is the third leading cause of hospitalization in the US. Exacerbations - a worsening or “flare up” of symptoms - cause most COPD hospitalizations. Since most exacerbations can be treated with changes of inhalers and/or oral medications, at-home detection of lung function deterioration may facilitate earlier intervention and help delay or pre ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Pharmacological chaperones for the treatment of Open-Angle Glaucoma
SBC: Viewpoint Therapeutics, Inc. Topic: NEIOpen-angle glaucoma is the second leading cause of blindness worldwide, affecting nearly 70 million individuals. Nonsynonymous mutations in the myocilin gene lead to the most common hereditary form of open-angle glaucoma and account for 3-4% of all cases. Disease-causing mutations, localized to its olfactomedin domain (mOLF), destabilize the myocilin protein, leading to its misfolding and accumula ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A Genes-to-Molecules Platform for Expanding Natural Product Diversity
SBC: Lassogen, Inc. Topic: NCCIHProject Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health